Lantheus Holdings, Inc. (LNTH)

NASDAQ: LNTH · IEX Real-Time Price · USD
88.67
-0.41 (-0.46%)
At close: Jun 2, 2023, 4:00 PM
88.65
-0.02 (-0.02%)
After-hours: Jun 2, 2023, 7:29 PM EDT
-0.46%
Market Cap 6.06B
Revenue (ttm) 1.03B
Net Income (ttm) -17.70M
Shares Out 68.33M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE 31.45
Dividend n/a
Ex-Dividend Date n/a
Volume 797,065
Open 89.44
Previous Close 89.08
Day's Range 87.61 - 90.28
52-Week Range 47.46 - 100.85
Beta 0.66
Analysts Strong Buy
Price Target 120.80 (+36.24%)
Earnings Date May 4, 2023

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-label... [Read more]

Sector Healthcare
IPO Date Jun 25, 2015
Employees 698
Stock Exchange NASDAQ
Ticker Symbol LNTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $120.8, which is an increase of 36.24% from the latest price.

Price Target
$120.8
(36.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lantheus to Present at the Jefferies Healthcare Conference

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and arti...

1 day ago - GlobeNewsWire

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

BEDFORD, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artif...

1 week ago - GlobeNewsWire

Lantheus Reports First Quarter 2023 Financial Results

BEDFORD, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and arti...

1 month ago - GlobeNewsWire
}

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiothe...

1 month ago - GlobeNewsWire

Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, M...

1 month ago - GlobeNewsWire

Lantheus Announces Two Key Executive Promotions

Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer

2 months ago - GlobeNewsWire

Are These Medical Device Makers Getting Ready To Rally?

Large-cap medical device maker Stryker Corp. (NYSE: SYK) is consolidating along its 50-day moving average, a bullish sign as the stock takes a breather after a run-up that began last year.

Other symbols: ALGNPENSYK
3 months ago - MarketBeat

Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results

BEDFORD, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and art...

3 months ago - GlobeNewsWire
}

Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans Data presented at th...

3 months ago - GlobeNewsWire

Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, Fe...

4 months ago - GlobeNewsWire

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and art...

4 months ago - GlobeNewsWire

Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer's Disease

MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's Disease MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's Disease

4 months ago - GlobeNewsWire

Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference

NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeuti...

5 months ago - GlobeNewsWire
}

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...

5 months ago - GlobeNewsWire

Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

NORTH BILLERICA, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal amoun...

6 months ago - GlobeNewsWire

Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

NORTH BILLERICA, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions a...

6 months ago - GlobeNewsWire

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeuti...

6 months ago - GlobeNewsWire

Lantheus to Present at the Jefferies London Healthcare Conference

NORTH BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeuti...

7 months ago - GlobeNewsWire

Lantheus Reports Third Quarter 2022 Financial Results

NORTH BILLERICA, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), a company committed to improving patient outcomes through diagnostics, radiotherapeutics an...

7 months ago - GlobeNewsWire

Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thur...

8 months ago - GlobeNewsWire

Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data

NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics...

8 months ago - GlobeNewsWire

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

CHALFONT ST GILES, United Kingdom and NORTH BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinica...

9 months ago - GlobeNewsWire

Lantheus to Present at the Wells Fargo Healthcare Conference

NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnosti...

9 months ago - GlobeNewsWire

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thur...

11 months ago - GlobeNewsWire

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations

1 year ago - GlobeNewsWire